Loading stock data…
Pacira BioSciences (PCRX)
$25.88-0.05 (-0.19%)
Market ClosedLast close Jul 24
Pacira BioSciences, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Pacira BioSciences, Inc. in the Healthcare sector is trading at $25.88 with a market capitalization of $897M. Wall Street consensus targets $29.67 (6 analysts), implying a +14.6% move over the next 12 months. The stock is currently near its 52-week high of $27.64, remaining 10.6% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +14.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $177.38M↓ | $196.87M↑ | $179.52M↓ | $181.10M↑ | $168.92M |
| Gross Profit | $140.96M↓ | $156.57M↑ | $145.24M↑ | $140.23M↑ | $134.62M |
| Operating Income | $4.63M↑ | -$10.92M↓ | $13.15M↑ | $9.13M↑ | $8.18M |
| Net Income | $2.92M↑ | $1.64M↓ | $5.43M↑ | -$4.85M↓ | $4.81M |
Peer Comparison
JNJUNHPFE
Fundamentals
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupiva...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$897.13M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
0.79%
Volume
Today's trading volume
409,401
Recent News
PCRX's Exparel Wins Separate Reimbursement From UnitedHealthcare
Pacira gains a reimbursement boost as UnitedHealthcare separately covers Exparel in outpatient care, expanding access to non-opioid postsurgical pain treatment.
Zimmer Biomet (ZBH) Is Buying Pacira’s Iovera Device And Expanding Into Spasticity
Zimmer Biomet Holdings (NYSE:ZBH) agreed to acquire Pacira BioSciences’ FDA cleared iovera pain relief device. The agreement includes a collaboration between the companies to advance the iovera spasticity program. The transaction is expected to close in the third quarter of 2026, subject to customary conditions. Zimmer Biomet operates as a large medical device company with a core focus on orthopedics and related surgical solutions. The planned addition of the iovera device extends its reach...
Zimmer Biomet to acquire iovera device from Pacira for $140m
The milestone payments may be achieved up to and through 31 December 2031.
Update: S&P 500, Nasdaq Composite Close Strongest Quarter in Six Years Amid Gains in Technology, Decline in Crude Oil
(Updates with index/price moves, macroeconomic data, and company/geopolitical news from the first pa
Sector Update: Healthcare Stocks Softer Late Afternoon
Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index decreasing 0.9%